First published in The Pharma Letter on October 20, 2025

From skeptic to builder: why I changed my mind about AI for biology

By: Albi Celaj, Head of ML Research, Deep Genomics

In 2014, I sat in a room at a “Genetic Networks” conference listening ...

First published on Pharmaphorum on August 14, 2025

The TechBio way: Brendan Frey talks genomics, AI, and RNA

Overall, the pharmaceutical industry is moving away from an approach where AI is task-driven, narrowly focused on a single, isolated problem. Instead, companies are embracing foundation models ...

First published in STAT+ on June 18, 2025

Why AI for drug discovery will far exceed current expectations 

The usual biotech metric of “how many AI drugs are in the clinic?” misses the point

By Brendan Frey, Chief Innovation Officer and Co-founder of Deep Genomics ...

Deep Genomics Expands AI Foundation Model Platform for Decoding RNA Biology

Deep Genomics, the AI-first TechBio organization pioneering a new path for genomic R&D, today announced the latest addition to its foundation model platform. The new deep learning model, REPRESS, accurately predicts microRNA (miRNA) binding ...

First published on MedCity News on September 4, 2024

RNA Foundation Models to Improve Pharma R&D Productivity

As RNA biology and RNA therapeutics emerge in the mainstream of pharma, RNA foundation models offer massive potential for revolutionizing R&D.

By Brendan Frey, Chief Innovation Officer and ...

First published on Medicine Maker on August 27, 2024

Why Pharma Must Embrace AI and Open Source

With open minds and open sources, the future is foundational – and bright.

By Brendan Frey, Chief Innovation Officer and Co-founder of Deep Genomics 

The cost of bringing new ...

First published in The Pharma Letter on July 4, 2024

Getting the most out of AI foundation models: tips for pharmaceutical companies

By Brendan Frey,  Founder and Chief Innovation Officer of Deep Genomics     

We’ve all heard of and used ChatGPT. But what if we ...

3 biotechs lease space at Cambridge office-to-lab conversion

First published by Greg Ryan – Senior Reporter at the Boston Business Journal on May 22, 2024

A Tishman Speyer joint venture has signed small leases with three biotechs at a Cambridge office-to-lab conversion, leaving about two-thirds of ...